Cookie Policy

This site uses cookies to improve your user experience. By using this website, you agree that we can place cookies on your device. For further information, please read ourPrivacy And Cookies Policy

I accept the terms and conditions
Skip Ribbon Commands
Skip to main content

QuiremSpheres® is indicated for the treatment of advanced unresectable liver tumors.

QuiremSpheres® microspheres have the same mode of action as existing Yttrium-90 based SIRT products: the microspheres emit beta radiation that kills tumor cells from close range. In addition, QuiremSpheres® can be visualized with SPECT and MR imaging, even in low concentrations. This is unique and cannot be done with currently available Yttrium-90 based microspheres.

Unique

The first and only commercial SIRT solution based on holmium-166. 

Proven

Based on more than 15 years of technological advancement and clinical research.

Visible on multi-modality imaging

Quantitative SPECT and MR imaging properties enable dosimetric treatment verification.

QuiremSpheres®: a complete SIRT solution

We deliver a complete SIRT solution, for which we have put your convenience as a starting point. This translates into:

  • QuiremSpheres® is patient-specific.
    QuiremSpheres® is convenient and easy to use since it is delivered to your hospital as a patient-specific, ready-to-use product.
  • A user-friendly administration box that has been designed with input from leading KOL's in the field of SIRT.
    QuiremSpheres® comes with a next generation SIRT administration device. The QuiremSpheres® Customer Kit, which was developed in co-creation with leading KOL's, is easy to use, simple/convenient to (dis)assemble and clean and provides excellent shielding of beta and gamma radiation.
  • Q-Suite™: a software tool to convert SPECT and/or MRI images into 3D dose distributions (DICOM format).
    To help you achieve quantitative dosimetric insight in your SIRT treatments as a means to drive treatment efficacy, we provide our in-house developed and CE-marked software tool Q-Suite™.
Read more Read less
  • ​QuiremSpheres® consists of biocompatible poly-L-lactic acid (PLLA) microspheres containing holmium-166.
  • The microspheres have a mean diameter of 30 micrometer (97% between 15 to 60 micrometer).
  • Holmium-166 is a high-energy beta emitting isotope for therapeutic use. The maximum energy of the beta particles is 1.85 MeV (50.0%) and 1.77MeV (48.7%).
  • Holmium-166 emits primary gamma photons (81 KeV). The half-life is 26.8 hours, meaning that more than 90% of the radiation is delivered within the first 4 days following the implantation procedure.

​QuiremSpheres® is supplied as a standard dose in a single capped V-vial or as a standard dose divided among several capped V-vials.

 

QuiremSpheres®
IsotopeHolmium-166​Yt-90
Beta-radiation (Emax)1.77 MeV (48.7%)
1.85 MeV (50.0%)
2.28 MeV
Gamma-radiation81 keV (6.7%)-
Visible on MRIYesNo
Half-life26.8 hours64.1 hours
MaterialPoly(L-lactic acid)Resin (r) or glass (g)
Diameter15-60 μm20-60 μm (r) 
20-30 μm (g)
Density1.4 g/cm31.6 g/cm3 (r) 
3.3 g/cm3 (g)

​QuiremSpheres® is a product manufactured by Quirem Medical B.V. and has CE-mark.

QuiremSpheres® is not available for sale in all countries. This information is provided only in respect to markets where the product is approved or cleared. QuiremSpheres® is not FDA cleared in the US for sale.

QuiremSpheres® is not approved in Canada

​QuiremSpheres® is a product manufactured by Quirem Medical B.V. and has CE-mark.

QuiremSpheres® is not available for sale in all countries. This information is provided only in respect to markets where the product is approved or cleared. QuiremSpheres® is not FDA cleared in the US for sale.

QuiremSpheres® is not approved in Canada

 

 

Hepar 1http://www.terumo-europe.com/en-emea/clinicaldata/hepar-1Hepar 1<p>​<sup>166</sup>Ho radioembolization is feasible and safe<sup>1</sup> for the treatment of patients with unresectable and chemorefractory liver metastases and enables image-guided treatment.</p>HayabusaArticlePage
Hepar 2http://www.terumo-europe.com/en-emea/clinicaldata/hepar-2Hepar 2<p>​Radioembolization with <sup>166</sup>Ho microspheres induced a tumor response with an acceptable toxicity profile in patients with liver metastases.</p>HayabusaArticlePage

 

 

 

 

 

 

QuiremSpheres FAQs http://www.terumo-europe.com/Relevant Product Info/QuiremSpheres FAQs.pdfQuiremSpheres FAQs 14/09/2017 22:00:00{6992E051-00C4-459A-A13D-EDA0BB7DBB07}HayabusaArticleDocument77054ba1-476b-4af3-b914-9a049e0b9ba8

Did you not find the product you were looking for ?